We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in prophylaxis, but also in therapy, when virus has already colonized host tissues. The observed net effect of IL-2 was consistent with the assumption of daily effector population doublings. The prospects for IL-2-supported immunotherapy of established CMV infection depend upon the tissues involved in disease. It appears that the prospects for controlling established CMV adrenalitis are less promising than for a therapy of interstitial CMV pneumonia.
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection.
- Views Icon Views
- PDF LinkPDF
- Share Icon Share
- Search Site
M J Reddehase, W Mutter, U H Koszinowski; In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection.. J Exp Med 1 March 1987; 165 (3): 650–656. doi: https://doi.org/10.1084/jem.165.3.650
Download citation file: